Mylan’s Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne(R) Tablets
PITTSBURGH, Aug. 29 - Mylan Inc. (NYSE: MYL)
today announced that its subsidiary Alphapharm Pty Limited won a favorable
decision in patent litigation against it and Barr Laboratories Inc.
relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil’s
Razadyne(R) Tablets, 4 mg, 8 mg and 12 mg.
On August 27, the U.S. District Court for the District of Delaware
invalidated [...]
Pharmaderm Annnounces the Arrival of KEROL(TM) ZX and KEROL(TM) Emulsion to Market
FLORHAM PARK, N.J., Aug. 29 - Today PharmaDerm, a
division of Nycomed US, announced the launch of KEROL ZX and KEROL Emulsion
to the dermatology and podiatry markets. These specialty products have been
developed for improved treatment of dry skin and damaged nails:
— KEROL Emulsion (NDC#10337-646-10) is supplied in a 10oz. tube for
application to larger skin surface areas.
[...]
CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
ST. LOUIS, Aug. 29 - CMS, Inc., an Elekta Company and
worldwide leader in radiation treatment planning and workflow management
solutions, today announced that three sites have delivered clinical
treatments utilizing Monaco(TM), its next-generation Intensity Modulated
Radiotherapy (IMRT) treatment planning system. Allegheny General Hospital
in Pittsburgh, Pennsylvania, Erasmus Medical Center in Rotterdam,
Netherlands, and Froedtert Memorial Lutheran Hospital in Milwaukee,
Wisconsin, have all [...]
Court Rejects Two Medtronic Patents
NATICK, Mass., Aug. 29 - Boston Scientific
Corporation (NYSE: BSX) today announced that the U.S. District Court of
Marshall, Texas found two patents of Medtronic, Inc. (NYSE: MDT)
unenforceable for inequitable conduct during the prosecution of the patents
before the United States Patent and Trademark Office.
A jury had previously found that certain Boston Scientific balloon
catheters and stent delivery systems [...]
Alseres Pharmaceuticals Announces Preclinical Study Results Demonstrating that Rho Inhibitors Could Be Useful in Promoting Bone Healing
HOPKINTON, Mass., Aug. 28 – Alseres
Pharmaceuticals, Inc., (Nasdaq: ALSE), announced that data from preclinical
studies of the Company’s regenerative therapy candidate, ALSE-100, were
presented at the Australian and New Zealand Bone and Mineral Society Annual
Conference, August 28-30, 2008 in Melbourne, Australia.
The poster presentation entitled: “Rho Inhibitor (ALSE-100) effects on
bone cells in vitro” highlighted the results of [...]
Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
VIENNA, Austria, Aug. 28 – Intercell AG (VSE: ICLL) today
announced that its collaborator Merck & Co., Inc. has initiated a Phase II
clinical trial of V710, an investigational vaccine for the prevention of
Staphylococcus aureus (S. aureus) infections. This randomized double blind,
placebo controlled study aims to evaluate the safety and immunogenicity of
the vaccine candidate in patients with [...]
MDS Pharma Services Strengthens Medical Leadership in Phase IIa Clinical Research
KING OF PRUSSIA, PA, Aug. 28 – MDS Pharma
Services, a leading provider of innovative drug discovery and development
solutions, has hired Ross Tonkens, MD, to provide medical oversight for its
Phase IIa clinical research activities and to direct the medical and
clinical activities of its Development & Regulatory Services line of
business. As Vice President – Medical Affairs, Dr. [...]
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
OSLO, August 28 — Results Further Support the Clinical Profile of
This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients
With Hormone Refractory Prostate Cancer (HRPC)
Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company,
today announced that the primary objective of its BC1-03 Phase II pain
palliation study was met. The study showed that even single [...]
DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
CUPERTINO, Calif., Aug. 27 — DURECT Corporation
(Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its
licensee, has submitted an Investigational New Drug (IND) application to
the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid
pain drug candidate based on DURECT’s patented ORADUR(TM) technology. This
is the third ORADUR-based opioid drug candidate covered by DURECT’s
collaboration with [...]
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
CAMBRIDGE, Mass., Aug. 27 — Millennium: The Takeda
Oncology Company today announced the publication of results from the 682
patient, randomized, Phase III VISTA(1) trial in this week’s edition of the
New England Journal of Medicine. The results showed a significant survival
benefit and a 30 percent complete remission (CR) rate with VELCADE,
melphalan and prednisone (VcMP) compared to 4 [...]
